Today: 30 April 2026
Browse Category

NASDAQ:BLUE 9 August 2025 - 17 August 2025

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

The FDA approved Boehringer Ingelheim’s lung cancer drug Hernexeos and a companion diagnostic on Aug 8, citing trial data showing tumor shrinkage in 75% of eligible patients. The agency restricted Bluebird Bio’s Skysona gene therapy to patients lacking a matched donor due to blood cancer risk. Stealth BioTherapeutics’ Barth syndrome drug was rejected for a third time. The FDA declared the U.S. IV saline shortage over.
9 August 2025
··

Stock Market Today

  • Why Investors Are Focused on Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) Amid Growth and High Insider Ownership
    April 29, 2026, 10:29 PM EDT. Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) has attracted investor attention due to its strong financial performance and insider alignment. The company has delivered a compound annual EPS growth of 19% over the past three years, signaling sustained earnings momentum. Revenue growth and an improved EBIT margin, up by 6.6 percentage points to 11%, underscore operational strength. With insiders owning 78% of the firm, alignment between management and shareholders is notably high, reducing agency risk. Valued at ₹2.5 billion, the company appeals to investors favoring profitable, growing firms over speculative ventures without revenue or profit history. This combination of growth, profitability, and insider confidence makes Vaidya Sane a compelling pick in the Ayurvedic healthcare sector.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Go toTop